Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Diffuse Large B-Cell Lymphoma Refractory × loncastuximab tesirine × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 16 Lymphoma 8 Lymphoma, Follicular 6 Lymphoma, Mantle-Cell 5 Lymphoma, B-Cell 4 Lymphoma, Non-Hodgkin 3 Waldenstrom Macroglobulinemia 2 Recurrence 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Burkitt Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, B-Cell, Marginal Zone 1 Diffuse Large B-Cell Lymphoma Refractory 1

Interventions

loncastuximab tesirine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03589469 2023-08-29

LOTIS-2

ADC Therapeutics S.A.

Phase 2 Completed

145 enrolled 24 charts 2 FDA

Diffuse Large B-Cell Lymphoma Refractory

Data powered by HemOnc (CC BY 4.0) Colophon ⚡